(Q39005896)

8 September 2017

1 reference

title

Transcriptional Regulation by Wild-Type and Cancer-Related Mutant Forms of p53. (English)

1 reference

8 September 2017

2

Carol Prives

1 reference

8 September 2017

Neil T Pfister

1

1 reference

8 September 2017

11 November 2016

1 reference

Cold Spring Harbor Perspectives in Medicine

8 September 2017

1 reference

8 September 2017

7

1 reference

8 September 2017

2

1 reference

A Mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis

8 September 2017

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Deciphering the transcriptional histone acetylation code for a human gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

p53 mutations and survival in stage I non-small-cell lung cancer: results of a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Differential regulation of the REGγ-proteasome pathway by p53/TGF-β signalling and mutant p53 in cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Ordered cooperative functions of PRMT1, p300, and CARM1 in transcriptional activation by p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Recruitment of p300/CBP in p53-dependent signal pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Sequence analysis of mutations and translocations across breast cancer subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Wild-type but not mutant p53 immunopurified proteins bind to sequences adjacent to the SV40 origin of replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Site-specific binding of wild-type p53 to cellular DNA is inhibited by SV40 T antigen and mutant p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

A proteolytic fragment from the central region of p53 has marked sequence-specific DNA-binding activity when generated from wild-type but not from oncogenic mutant p53 protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Transcriptional regulation by p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Regulation of p53--insights into a complex process

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Conditional RNA interference in vivo to study mutant p53 oncogenic gain of function on tumor malignancy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Constitutive DNase I hypersensitivity of p53-regulated promoters

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Distinct p53 transcriptional programs dictate acute DNA-damage responses and tumor suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Mutant p53 protects cells from 12-O-tetradecanoylphorbol-13-acetate-induced death by attenuating activating transcription factor 3 induction

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Polybromo-associated BRG1-associated factor components BRD7 and BAF180 are critical regulators of p53 required for induction of replicative senescence

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Cancer chemoresistance: the relationship between p53 and multidrug transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Integrated genomic analyses of ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Integrated genomic characterization of papillary thyroid carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

An inducible mouse model for skin cancer reveals distinct roles for gain- and loss-of-function p53 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Transactivation ability of p53 transcriptional activation domain is directly related to the binding affinity to TATA-binding protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Mutant p53 forms a complex with Sp1 on HIV-LTR DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Modulation of activity of the promoter of the human MDR1 gene by Ras and p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Mutant p53 prolongs NF-κB activation and promotes chronic inflammation and inflammation-associated colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Integration of TGF-beta and Ras/MAPK signaling through p53 phosphorylation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

p73 and p63 are homotetramers capable of weak heterotypic interactions with each other but not with p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Detection of a transformation-related antigen in chemically induced sarcomas and other transformed cells of the mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

ChIP-on-chip analysis of in vivo mutant p53 binding to selected gene promoters.

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

The human Mi-2/NuRD complex and gene regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Gain of function of mutant p53: the mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

The disruption of the protein complex mutantp53/p73 increases selectively the response of tumor cells to anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Mutant p53 reprograms TNF signaling in cancer cells through interaction with the tumor suppressor DAB2IP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Gain of function mutations in p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Mutant p53 cooperates with ETS2 to promote etoposide resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Identification of RB18A, a 205 kDa new p53 regulatory protein which shares antigenic and functional properties with p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Evolution of the SNF2 family of proteins: subfamilies with distinct sequences and functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Definition of a consensus binding site for p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

WAF1, a potential mediator of p53 tumor suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Participation of p53 cellular tumour antigen in transformation of normal embryonic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Mediator-dependent recruitment of TFIIH modules in preinitiation complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Mechanisms of regulatory diversity within the p53 transcriptional network

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Transcriptional regulation by p53 through intrinsic DNA/chromatin binding and site-directed cofactor recruitment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Diverse roles and interactions of the SWI/SNF chromatin remodeling complex revealed using global approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Cell cycle-dependent nuclear retention of p53 by E2F1 requires phosphorylation of p53 at Ser315.

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Ligand induction of a transcriptionally active thyroid hormone receptor coactivator complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

The execution of the transcriptional axis mutant p53, E2F1 and ID4 promotes tumor neo-angiogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

RB18A regulates p53-dependent apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Activation of c-myc gene expression by tumor-derived p53 mutants requires a discrete C-terminal domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Mutant p53: one name, many proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

A transcriptionally active DNA-binding site for human p53 protein complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

A Pin1/mutant p53 axis promotes aggressiveness in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Immunity, Inflammation, and Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Synergistic activation of transcription by CBP and p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

A novel human SRB/MED-containing cofactor complex, SMCC, involved in transcription regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

p53 and Sp1 interact and cooperate in the tumor necrosis factor-induced transcriptional activation of the HIV-1 long terminal repeat

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

An oncogenic form of p53 confers a dominant, gain-of-function phenotype that disrupts spindle checkpoint control

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Mutant p53-induced up-regulation of mitogen-activated protein kinase kinase 3 contributes to gain of function

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Two hot spot mutant p53 mouse models display differential gain of function in tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Protein arginine methyltransferase 1 coactivates NF-kappaB-dependent gene expression synergistically with CARM1 and PARP1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Promyelocytic leukemia protein is required for gain of function by mutant p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Mutant p53(R270H) gain of function phenotype in a mouse model for oncogene-induced mammary carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Methylation of histone H4 by arginine methyltransferase PRMT1 is essential in vivo for many subsequent histone modifications

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Wild-type p53 controls cell motility and invasion by dual regulation of MET expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Direct p53 transcriptional repression: in vivo analysis of CCAAT-containing G2/M promoters.

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Mutant p53 promotes tumor cell malignancy by both positive and negative regulation of the transforming growth factor β (TGF-β) pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Structural biology of the tumor suppressor p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Structures of p53 cancer mutants and mechanism of rescue by second-site suppressor mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Structural basis for understanding oncogenic p53 mutations and designing rescue drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

TFIID and human mediator coactivator complexes assemble cooperatively on promoter DNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

The p53QS transactivation-deficient mutant shows stress-specific apoptotic activity and induces embryonic lethality

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Mutant p53 attenuates the SMAD-dependent transforming growth factor beta1 (TGF-beta1) signaling pathway by repressing the expression of TGF-beta receptor type II

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Cancer-associated p53 tetramerization domain mutants: quantitative analysis reveals a low threshold for tumor suppressor inactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Effects of mutant p53 expression on human 15-lipoxygenase-promoter activity and murine 12/15-lipoxygenase gene expression: evidence that 15-lipoxygenase is a mutator gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Identification of p53 as a sequence-specific DNA-binding protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

The complex interactions of p53 with target DNA: we learn as we go.

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Transcriptional activities of mutant p53: when mutations are more than a loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Interactions of mutant p53 with DNA: guilt by association

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Tumor suppressor p53 inhibits transcriptional activation of invasion gene thromboxane synthase mediated by the proto-oncogenic factor ets-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Regulation of nucleotide metabolism by mutant p53 contributes to its gain-of-function activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Physical and functional interactions between members of the tumour suppressor p53 and the Sp families of transcription factors: importance for the regulation of genes involved in cell-cycle arrest and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Wild-type p53 is a cell cycle checkpoint determinant following irradiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Nucleosome disruption and enhancement of activator binding by a human SW1/SNF complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

T antigen is bound to a host protein in SY40-transformed cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Transcriptional regulation by p53: one protein, many possibilities

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

p53 binding to nucleosomes within the p21 promoter in vivo leads to nucleosome loss and transcriptional activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Gal-3 is stimulated by gain-of-function p53 mutations and modulates chemoresistance in anaplastic thyroid carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Activation of the insulin-like growth factor II transcription by aflatoxin B1 induced p53 mutant 249 is caused by activation of transcription complexes; implications for a gain-of-function during the formation of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

SWI/SNF complex interacts with tumor suppressor p53 and is necessary for the activation of p53-mediated transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Cell signaling by receptor tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Are interactions with p63 and p73 involved in mutant p53 gain of oncogenic function?

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

PTEN has tumor-promoting properties in the setting of gain-of-function p53 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

p53 binds preferentially to genomic regions with high DNA-encoded nucleosome occupancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Binding and modulation of p53 by p300/CBP coactivators

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Mutant p53 mediates survival of breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Characterization of a 54K Dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

High metastatic potential in mice inheriting a targeted p53 missense mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

TopBP1 mediates mutant p53 gain of function through NF-Y and p63/p73.

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

RB18A enhances expression of mutant p53 protein in human cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Transcriptional activation of the human epidermal growth factor receptor promoter by human p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Deacetylation of p53 modulates its effect on cell growth and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

The prolyl isomerase Pin1 orchestrates p53 acetylation and dissociation from the apoptosis inhibitor iASPP

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

A common polymorphism acts as an intragenic modifier of mutant p53 behaviour

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Integrity of the N-terminal transcription domain of p53 is required for mutant p53 interference with drug-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

p53 activates transcription by directing structural shifts in Mediator

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Mutant p53 drives invasion by promoting integrin recycling

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Mutant p53 enhances MET trafficking and signalling to drive cell scattering and invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Human CRSP interacts with RNA polymerase II CTD and adopts a specific CTD-bound conformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

DNA bending is essential for the site-specific recognition of DNA response elements by the DNA binding domain of the tumor suppressor protein p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

The SWI/SNF chromatin remodeling subunit BRG1 is a critical regulator of p53 necessary for proliferation of malignant cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

PUMA, a novel proapoptotic gene, is induced by p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Mutations in the p53 gene occur in diverse human tumour types

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Set9, a novel histone H3 methyltransferase that facilitates transcription by precluding histone tail modifications required for heterochromatin formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

BAF60a interacts with p53 to recruit the SWI/SNF complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

TP53 mutations in human cancers: origins, consequences, and clinical use

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Mutant p53 gain-of-function in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

The presence of TP53 mutation at diagnosis of follicular lymphoma identifies a high-risk group of patients with shortened time to disease progression and poorer overall survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Cooperation between gene encoding p53 tumour antigen and ras in cellular transformation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

The blockade of immune checkpoints in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Mutant p53 cooperates with the SWI/SNF chromatin remodeling complex to regulate VEGFR2 in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

p53 increases experimental metastatic capacity of murine carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Tumor-derived p53 mutant C174Y is a gain-of-function mutant which activates the fos promoter and enhances colony formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Novel gain of function activity of p53 mutants: activation of the dUTPase gene expression leading to resistance to 5-fluorouracil

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Mutant p53 is a transcriptional co-factor that binds to G-rich regulatory regions of active genes and generates transcriptional plasticity

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Transcriptional control of human p53-regulated genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Mutations in the p53 Tumor Suppressor Gene: Important Milestones at the Various Steps of Tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Dietary downregulation of mutant p53 levels via glucose restriction: mechanisms and implications for tumor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

p53, a transformation-related cellular-encoded protein, can be used as a biochemical marker for the detection of primary mouse tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

p53 binding to nucleosomal DNA depends on the rotational positioning of DNA response element

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Prognostic significance of p53 mutations in colon cancer at the population level

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Mutant p53 cooperates with ETS and selectively up-regulates human MDR1 not MRP1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Upregulation of the mitochondrial transport protein, Tim50, by mutant p53 contributes to cell growth and chemoresistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Tumor-derived p53 mutants induce oncogenesis by transactivating growth-promoting genes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Tumor-derived p53 mutants induce NF-kappaB2 gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Wild-type p53 binds to the TATA-binding protein and represses transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

The clonal and mutational evolution spectrum of primary triple-negative breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

The C-terminus of mutant p53 is necessary for its ability to interfere with growth arrest or apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Protumorigenic overexpression of stathmin/Op18 by gain-of-function mutation in p53 in human hepatocarcinogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Cofactor binding evokes latent differences in DNA binding specificity between Hox proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Various p53 mutant proteins differently regulate the Ras circuit to induce a cancer-related gene signature

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Reassessment of the TP53 mutation database in human disease by data mining with a library of TP53 missense mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Modulation of the vitamin D3 response by cancer-associated mutant p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Physical interaction with human tumor-derived p53 mutants inhibits p63 activities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Mutant p53: an oncogenic transcription factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

The region 3' to the major transcriptional start site of the MDR1 downstream promoter mediates activation by a subset of mutant P53 proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Regulating the p53 pathway: in vitro hypotheses, in vivo veritas

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Sp1-p53 heterocomplex mediates activation of HTLV-I long terminal repeat by 12-O-tetradecanoylphorbol-13-acetate that is antagonized by protein kinase C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Li-Fraumeni syndrome--a molecular and clinical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Gain-of-Function Activity of Mutant p53 in Lung Cancer through Up-Regulation of Receptor Protein Tyrosine Kinase Axl

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Definition of a p53 transactivation function-deficient mutant and characterization of two independent p53 transactivation subdomains

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Cancer-derived p53 mutants suppress p53-target gene expression--potential mechanism for gain of function of mutant p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Blinded by the Light: The Growing Complexity of p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Identification of a novel p53 functional domain that is necessary for efficient growth suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Mutant p53 drives pancreatic cancer metastasis through cell-autonomous PDGF receptor β signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Transactivation of the EGR1 gene contributes to mutant p53 gain of function

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Wild-type and mutant p53 differentially regulate transcription of the insulin-like growth factor I receptor gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Chromatin-bound p53 anchors activated Smads and the mSin3A corepressor to confer transforming-growth-factor-beta-mediated transcription repression

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

SWI/SNF nucleosome remodellers and cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Prevalence of early onset colorectal cancer in 397 patients with classic Li-Fraumeni syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Characterization of the CHD family of proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

BAF180 is a critical regulator of p21 induction and a tumor suppressor mutated in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Pla2g16 phospholipase mediates gain-of-function activities of mutant p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

The activity of p53 is differentially regulated by Brm- and Brg1-containing SWI/SNF chromatin remodeling complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

SNF5, a core component of the SWI/SNF complex, is necessary for p53 expression and cell survival, in part through eIF4E.

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Identification of GRO1 as a critical determinant for mutant p53 gain of function

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Characterization of functional domains necessary for mutant p53 gain of function

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Suppression of inhibitor of differentiation 2, a target of mutant p53, is required for gain-of-function mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Gain-of-function mutant p53 upregulates CXC chemokines and enhances cell migration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Histone H3 lysine 4 methylation disrupts binding of nucleosome remodeling and deacetylase (NuRD) repressor complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

MED1/TRAP220 exists predominantly in a TRAP/ Mediator subpopulation enriched in RNA polymerase II and is required for ER-mediated transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Identification of a novel p53 functional domain that is necessary for mediating apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Gain-of-function p53 mutants co-opt chromatin pathways to drive cancer growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Change of Conformation of the DNA-binding Domain of p53 Is the Only Key Element for Binding of and Interference with p73

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FCSHPERSPECT.A026054

Wild type and mutant p53 differentially regulate the gene expression of human collagenase-3 (hMMP-13)

21 January 2018

1 reference

12 December 2020

Understanding "active" chromatin: a historical perspective of chromatin remodeling

1 reference

12 December 2020

RB18A, whose gene is localized on chromosome 17q12-q21.1, regulates in vivo p53 transactivating activity

1 reference

12 December 2020

Acetylation of p53 activates transcription through recruitment of coactivators/histone acetyltransferases

1 reference

12 December 2020

Expression of mitotic spindle checkpoint protein hsMAD1 correlates with cellular proliferation and is activated by a gain-of-function p53 mutant.

1 reference

12 December 2020

Cooperation of two mutant p53 alleles contributes to Fas resistance of prostate carcinoma cells

1 reference

12 December 2020

Mutant p53 gain of function: repression of CD95(Fas/APO-1) gene expression by tumor-associated p53 mutants

1 reference

12 December 2020

Modulation of cellular and viral promoters by mutant human p53 proteins found in tumor cells

1 reference

12 December 2020

Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome

1 reference

12 December 2020

Oncogenic forms of p53 inhibit p53-regulated gene expression

1 reference

12 December 2020

Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression

1 reference

12 December 2020

Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form

1 reference

12 December 2020

Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines

1 reference

12 December 2020

p53-R273H gains new function in induction of drug resistance through down-regulation of procaspase-3

1 reference

12 December 2020

Mutant p53 enhances nuclear factor kappaB activation by tumor necrosis factor alpha in cancer cells

1 reference

12 December 2020

A comparison between p53 accumulation determined by immunohistochemistry and TP53 mutations as prognostic variables in tumours from breast cancer patients

1 reference

12 December 2020

Molecular basis of the Li-Fraumeni syndrome: an update from the French LFS families

1 reference

12 December 2020

P53 mutations in lymphomas: position matters

1 reference

12 December 2020

Patterns of expression of the p53 tumour suppressor in human breast tissues and tumours in situ and in vitro

1 reference

12 December 2020

p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis

1 reference

12 December 2020

Mutation is required to activate the p53 gene for cooperation with the ras oncogene and transformation

1 reference

12 December 2020

P53 expression in breast cancer

1 reference

12 December 2020

Mutations in p53 produce a common conformational effect that can be detected with a panel of monoclonal antibodies directed toward the central part of the p53 protein

1 reference

12 December 2020

p21 is necessary for the p53-mediated G1 arrest in human cancer cells

1 reference

12 December 2020

Two critical hydrophobic amino acids in the N-terminal domain of the p53 protein are required for the gain of function phenotypes of human p53 mutants.

1 reference

12 December 2020

Gain-of-function mutations of the p53 gene induce lymphohematopoietic metastatic potential and tissue invasiveness

1 reference

12 December 2020

Prognostic significance of p53 gene alterations in node-negative breast cancer

1 reference

12 December 2020

mdm2 expression is induced by wild type p53 activity

1 reference

12 December 2020

Wild-type but not mutant p53 can repress transcription initiation in vitro by interfering with the binding of basal transcription factors to the TATA motif

1 reference

12 December 2020

Two tandem and independent sub-activation domains in the amino terminus of p53 require the adaptor complex for activity

1 reference

12 December 2020

p53 represses Sp1 DNA binding and HIV-LTR directed transcription

1 reference

12 December 2020

p73 function is inhibited by tumor-derived p53 mutants in mammalian cells.

1 reference

12 December 2020

10.1101/CSHPERSPECT.A026054

Identifiers

DOI

1 reference

release_agqx7fgl2bbg7a3bgkzhhe7dbe

8 September 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/agqx7fgl2bbg7a3bgkzhhe7dbe

24 November 2022

mapped directly with Wikidata item

0 references

1 reference

PubMed ID

27836911